Journal of Experimental Medicine, Vol 147, 973-983, Copyright © 1978 by Rockefeller University Press

ARTICLES

Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis

VA Lennon, ME Seybold, JM Lindstrom, C Cochrane and R Ulevitch

An acute phase of experimental autoimmune myasthenia gravis (EAMG) occurs transiently early in the immune response of Lewis rats to nicotinic acetylcholine receptors (AChR) when Bordetella pertussis is used as adjuvant. It is characterized by a destructive cellular attack directed at the postsynaptic membranes of muscle. Acute EAMG can be passively transferred to normal rats by IgG from serum of rats with chronic EAMG. In the present study, acute EAMG, induced either by passive transfer of syngeneic antibodies or by active immmunization, was inhibited in rats depleted of complement by treatment with cobra venom factor (CoF). Furthermore, passive transfer of antibodies in excess of the muscle's content of AChR was without any measurable effect in rats treated with CoF. Although 60% of the muscle's AChR was complexed with antibody, there was no reduction in the muscle's content of AChR, and neuromuscular transmission was not compromised as judged electromyographically by curare sensitivity. These data imply that redistribution, accelerated degradation, and impairment of the ionophore function of AChR, effects of antibodies described in vitro on extrajunctional AChR, do not play a significant role in vivo in impairing neuromuscular transmission in an intact neuromuscular junction. Complement appears to be a critical mediator of anti-AChR antibodies' pathogenicity in vivo.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

• Zhou, Y., Gong, B., Lin, F., Rother, R. P., Medof, M. E., Kaminski, H. J. (2007). Anti-C5 Antibody Treatment Ameliorates Weakness in Experimentally Acquired Myasthenia Gravis. J. Immunol. 179: 8562-8567 [Abstract] [Full Text]  
• Sheng, J. R., Li, L., Ganesh, B. B., Vasu, C., Prabhakar, B. S., Meriggioli, M. N. (2006). Suppression of Experimental Autoimmune Myasthenia Gravis by Granulocyte-Macrophage Colony-Stimulating Factor Is Associated with an Expansion of FoxP3+ Regulatory T Cells. J. Immunol. 177: 5296-5306 [Abstract] [Full Text]  
• Losen, M., Stassen, M. H. W., Martinez-Martinez, P., Machiels, B. M., Duimel, H., Frederik, P., Veldman, H., Wokke, J. H. J., Spaans, F., Vincent, A., De Baets, M. H. (2005). Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis. Brain 128: 2327-2337 [Abstract] [Full Text]  
• Tuzun, E., Scott, B. G., Goluszko, E., Higgs, S., Christadoss, P. (2003). Genetic Evidence for Involvement of Classical Complement Pathway in Induction of Experimental Autoimmune Myasthenia Gravis. J. Immunol. 171: 3847-3854 [Abstract] [Full Text]  
• Quintana, F. J., Pitashny, M., Cohen, I. R. (2003). Experimental autoimmune myasthenia gravis in naive non-obese diabetic (NOD/LtJ) mice: susceptibility associated with natural IgG antibodies to the acetylcholine receptor. Int Immunol 15: 11-16 [Abstract] [Full Text]  
• Saoudi, A., Bernard, I., Hoedemaekers, A., Cautain, B., Martinez, K., Druet, P., De Baets, M., Guery, J.-C. (1999). Experimental Autoimmune Myasthenia Gravis May Occur in the Context of a Polarized Th1- or Th2-Type Immune Response in Rats. J. Immunol. 162: 7189-7197 [Abstract] [Full Text]  
• Makrides, S. C. (1998). Therapeutic Inhibition of the Complement System. Pharmacol. Rev. 50: 59-88 [Abstract] [Full Text]  
• Balasa, B., Deng, C., Lee, J., Bradley, L. M., Dalton, D. K., Christadoss, P., Sarvetnick, N. (1997). Interferon {gamma} (IFN-{gamma}) Is Necessary for the Genesis of Acetylcholine Receptor-induced Clinical Experimental Autoimmune Myasthenia gravis in Mice. JEM 186: 385-391 [Abstract] [Full Text]  
• McNamara, J.O., Patel, M., He, X.-P., Janumpalli, S., Whitney, K.D. (1996). Glutamate Receptor Autoimmunity in Rasmussen's Encephalitis. Cold Spring Harb Symp Quant Biol 61: 327-332 [Abstract]  
• Weisman, H., Bartow, T, Leppo, M., Marsh, H. Jr, Carson, G., Concino, M., Boyle, M., Roux, K., Weisfeldt, M., Fearon, D. (1990). Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249: 146-151 [Abstract]  
• Seybold, M. E. (1983). Myasthenia Gravis: A Clinical and Basic Science Review. JAMA 250: 2516-2521 [Abstract]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS